 Dong Miao
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autoantibodies | 31 | 2022 | 1335 | 2.140 |
Why?
| | Diabetes Mellitus, Type 1 | 32 | 2022 | 3360 | 1.320 |
Why?
| | Glutamate Decarboxylase | 10 | 2022 | 159 | 1.290 |
Why?
| | Insulin Antibodies | 10 | 2016 | 101 | 1.080 |
Why?
| | Prediabetic State | 6 | 2015 | 234 | 1.020 |
Why?
| | Luminescence | 4 | 2016 | 34 | 0.810 |
Why?
| | Celiac Disease | 8 | 2022 | 267 | 0.730 |
Why?
| | Luminescent Measurements | 6 | 2021 | 72 | 0.690 |
Why?
| | Islets of Langerhans | 12 | 2019 | 739 | 0.460 |
Why?
| | Transglutaminases | 5 | 2016 | 143 | 0.430 |
Why?
| | Lipoproteins, HDL | 1 | 2011 | 82 | 0.400 |
Why?
| | Sensitivity and Specificity | 12 | 2022 | 1795 | 0.390 |
Why?
| | Mass Screening | 6 | 2021 | 1052 | 0.380 |
Why?
| | Hyperlipidemias | 1 | 2011 | 128 | 0.380 |
Why?
| | Insulin | 13 | 2016 | 2162 | 0.360 |
Why?
| | Carotid Arteries | 1 | 2011 | 184 | 0.360 |
Why?
| | Proinsulin | 5 | 2013 | 48 | 0.350 |
Why?
| | Electrochemical Techniques | 2 | 2020 | 39 | 0.350 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 374 | 0.310 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2016 | 51 | 0.300 |
Why?
| | Vascular Stiffness | 1 | 2011 | 425 | 0.280 |
Why?
| | Peptide Fragments | 6 | 2004 | 702 | 0.260 |
Why?
| | Autoantigens | 3 | 2009 | 397 | 0.260 |
Why?
| | Zinc Transporter 8 | 3 | 2021 | 63 | 0.250 |
Why?
| | Epitopes | 2 | 2005 | 443 | 0.240 |
Why?
| | Hypertension | 1 | 2011 | 1203 | 0.210 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2004 | 145 | 0.210 |
Why?
| | Predictive Value of Tests | 6 | 2015 | 1868 | 0.210 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 256 | 0.200 |
Why?
| | Biomarkers | 5 | 2022 | 3588 | 0.190 |
Why?
| | Poly I-C | 3 | 2005 | 55 | 0.180 |
Why?
| | Health Fairs | 1 | 2019 | 9 | 0.180 |
Why?
| | Genotype | 5 | 2015 | 1882 | 0.160 |
Why?
| | Child, Preschool | 13 | 2019 | 9491 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2174 | 0.160 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 122 | 0.160 |
Why?
| | Steroid 21-Hydroxylase | 2 | 2009 | 29 | 0.150 |
Why?
| | Addison Disease | 2 | 2009 | 39 | 0.150 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 398 | 0.150 |
Why?
| | China | 2 | 2021 | 175 | 0.150 |
Why?
| | Disease Progression | 6 | 2016 | 2490 | 0.140 |
Why?
| | Child | 15 | 2022 | 19129 | 0.140 |
Why?
| | Infant | 10 | 2019 | 8293 | 0.140 |
Why?
| | Membrane Proteins | 1 | 2002 | 1055 | 0.130 |
Why?
| | Risk Factors | 9 | 2021 | 9000 | 0.130 |
Why?
| | Female | 20 | 2021 | 61564 | 0.130 |
Why?
| | Humans | 29 | 2022 | 118972 | 0.130 |
Why?
| | Male | 16 | 2021 | 57801 | 0.120 |
Why?
| | Autoimmunity | 4 | 2016 | 831 | 0.120 |
Why?
| | Protein Precursors | 2 | 2004 | 126 | 0.110 |
Why?
| | Cation Transport Proteins | 2 | 2013 | 99 | 0.110 |
Why?
| | Radioimmunoassay | 4 | 2016 | 165 | 0.110 |
Why?
| | Adolescent | 11 | 2019 | 18480 | 0.110 |
Why?
| | Mice, Inbred NOD | 8 | 2005 | 574 | 0.110 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2005 | 211 | 0.110 |
Why?
| | Polymorphism, Genetic | 3 | 2009 | 642 | 0.100 |
Why?
| | Diastole | 1 | 2011 | 145 | 0.100 |
Why?
| | Incidence | 2 | 2021 | 2424 | 0.100 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2009 | 177 | 0.090 |
Why?
| | Risk | 1 | 2013 | 853 | 0.090 |
Why?
| | Health Surveys | 1 | 2011 | 454 | 0.090 |
Why?
| | Triglycerides | 1 | 2011 | 519 | 0.080 |
Why?
| | Interferon-alpha | 2 | 2009 | 191 | 0.080 |
Why?
| | Laboratories | 1 | 2009 | 97 | 0.080 |
Why?
| | Diagnostic Techniques, Endocrine | 2 | 2019 | 14 | 0.070 |
Why?
| | CD4 Antigens | 2 | 2003 | 126 | 0.070 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2004 | 45 | 0.070 |
Why?
| | Edible Grain | 1 | 2005 | 43 | 0.070 |
Why?
| | Glutens | 1 | 2005 | 56 | 0.060 |
Why?
| | Alanine | 1 | 2004 | 102 | 0.060 |
Why?
| | Mice | 13 | 2005 | 15520 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4596 | 0.060 |
Why?
| | Mice, Inbred BALB C | 5 | 2005 | 1206 | 0.060 |
Why?
| | Transgenes | 1 | 2004 | 174 | 0.060 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 86 | 0.060 |
Why?
| | Middle Aged | 5 | 2021 | 27617 | 0.060 |
Why?
| | Adult | 7 | 2021 | 31512 | 0.060 |
Why?
| | Young Adult | 5 | 2019 | 10793 | 0.060 |
Why?
| | Genetic Testing | 1 | 2005 | 389 | 0.060 |
Why?
| | Osteopontin | 1 | 2022 | 39 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2004 | 806 | 0.050 |
Why?
| | Prospective Studies | 5 | 2016 | 6471 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 827 | 0.050 |
Why?
| | Fetal Blood | 1 | 2004 | 272 | 0.050 |
Why?
| | HLA-DQ Antigens | 3 | 2009 | 176 | 0.050 |
Why?
| | Electrochemistry | 1 | 2021 | 69 | 0.050 |
Why?
| | Models, Immunological | 1 | 2002 | 94 | 0.050 |
Why?
| | Mice, Knockout | 5 | 2005 | 2680 | 0.050 |
Why?
| | Aged | 3 | 2021 | 19657 | 0.050 |
Why?
| | Phenotype | 3 | 2021 | 3003 | 0.050 |
Why?
| | Injections, Subcutaneous | 3 | 2004 | 138 | 0.040 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 34 | 0.040 |
Why?
| | Mice, Transgenic | 4 | 2005 | 2025 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 1798 | 0.040 |
Why?
| | Animals | 13 | 2005 | 33381 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3057 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 331 | 0.040 |
Why?
| | Antibody Specificity | 2 | 2011 | 184 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2016 | 1125 | 0.040 |
Why?
| | Biopsy | 2 | 2016 | 1079 | 0.040 |
Why?
| | Population Surveillance | 1 | 2020 | 413 | 0.040 |
Why?
| | Community Health Services | 1 | 2019 | 212 | 0.040 |
Why?
| | Diet | 1 | 2005 | 1153 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 3443 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2003 | 1284 | 0.040 |
Why?
| | Homozygote | 2 | 2009 | 190 | 0.040 |
Why?
| | Time Factors | 4 | 2016 | 6412 | 0.040 |
Why?
| | Age of Onset | 2 | 2011 | 467 | 0.040 |
Why?
| | HLA-DR Antigens | 2 | 2009 | 224 | 0.040 |
Why?
| | Disease Management | 1 | 2020 | 571 | 0.040 |
Why?
| | Peptides | 1 | 2002 | 879 | 0.040 |
Why?
| | Proteomics | 1 | 2022 | 876 | 0.040 |
Why?
| | Antibody Affinity | 1 | 2016 | 55 | 0.030 |
Why?
| | Blood Glucose | 3 | 2016 | 1939 | 0.030 |
Why?
| | C-Peptide | 1 | 2016 | 137 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1570 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1323 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 540 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5116 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2005 | 4908 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2005 | 984 | 0.030 |
Why?
| | Adoptive Transfer | 2 | 2005 | 204 | 0.030 |
Why?
| | Mice, SCID | 2 | 2005 | 333 | 0.030 |
Why?
| | Alleles | 2 | 2009 | 832 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2011 | 3171 | 0.030 |
Why?
| | Spleen | 2 | 2005 | 510 | 0.030 |
Why?
| | Administration, Oral | 2 | 2004 | 756 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2874 | 0.030 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 130 | 0.030 |
Why?
| | Graves Disease | 1 | 2009 | 32 | 0.020 |
Why?
| | HLA-DQ beta-Chains | 1 | 2009 | 61 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4196 | 0.020 |
Why?
| | Infant, Newborn | 3 | 2005 | 5255 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2513 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2009 | 97 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 143 | 0.020 |
Why?
| | Radioligand Assay | 1 | 2009 | 45 | 0.020 |
Why?
| | International Cooperation | 1 | 2009 | 177 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1384 | 0.020 |
Why?
| | ROC Curve | 1 | 2009 | 473 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2009 | 653 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1012 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1774 | 0.020 |
Why?
| | Thyroglobulin | 1 | 2005 | 18 | 0.020 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 25 | 0.020 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 22 | 0.020 |
Why?
| | Ovum | 1 | 2004 | 30 | 0.020 |
Why?
| | Microinjections | 1 | 2004 | 83 | 0.020 |
Why?
| | Crosses, Genetic | 1 | 2004 | 138 | 0.020 |
Why?
| | Family Health | 1 | 2005 | 201 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2004 | 123 | 0.020 |
Why?
| | HLA-DR4 Antigen | 1 | 2004 | 75 | 0.020 |
Why?
| | Organ Specificity | 1 | 2005 | 278 | 0.020 |
Why?
| | HLA-DR3 Antigen | 1 | 2004 | 77 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2004 | 115 | 0.020 |
Why?
| | B7-1 Antigen | 1 | 2004 | 69 | 0.020 |
Why?
| | Intestine, Small | 1 | 2005 | 131 | 0.020 |
Why?
| | Models, Biological | 1 | 2011 | 1715 | 0.020 |
Why?
| | Heterozygote | 1 | 2004 | 262 | 0.010 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 152 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 276 | 0.010 |
Why?
| | HLA Antigens | 1 | 2005 | 230 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 2004 | 157 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 269 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 2003 | 222 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 95 | 0.010 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2003 | 68 | 0.010 |
Why?
| | Isoenzymes | 1 | 2004 | 297 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 2004 | 125 | 0.010 |
Why?
| | Species Specificity | 1 | 2004 | 565 | 0.010 |
Why?
| | Hydrocortisone | 1 | 2004 | 273 | 0.010 |
Why?
| | DNA Primers | 1 | 2003 | 533 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 5690 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 460 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 71 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 97 | 0.010 |
Why?
| | Antibodies | 1 | 2003 | 392 | 0.010 |
Why?
| | Regression Analysis | 1 | 2004 | 983 | 0.010 |
Why?
| | Adjuvants, Immunologic | 1 | 2002 | 207 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2005 | 702 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1267 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2004 | 1158 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1489 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2159 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 4552 | 0.010 |
Why?
| | Prevalence | 1 | 2005 | 2326 | 0.010 |
Why?
| | Proteins | 1 | 2004 | 938 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 745 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2002 | 1691 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 1945 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5392 | 0.010 |
Why?
| | Vaccination | 1 | 2003 | 1222 | 0.010 |
Why?
| | Aging | 1 | 2005 | 1670 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2004 | 3730 | 0.010 |
Why?
|
|
Miao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|